Diagnostic accuracy of magnetic resonance diffusion tensor imaging in distinguishing pseudoprogression from glioma recurrence: a systematic review and meta-analysis.

IF 2.9 3区 医学 Q2 ONCOLOGY Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-10-14 DOI:10.1080/14737140.2024.2415404
Xiaoyi Wu, Mai Zhang, Quan Jiang, Mingxi Li, Yuankui Wu
{"title":"Diagnostic accuracy of magnetic resonance diffusion tensor imaging in distinguishing pseudoprogression from glioma recurrence: a systematic review and meta-analysis.","authors":"Xiaoyi Wu, Mai Zhang, Quan Jiang, Mingxi Li, Yuankui Wu","doi":"10.1080/14737140.2024.2415404","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the diagnostic accuracy of diffusion tensor imaging (DTI)-derived metrics mean diffusivity (MD) and fractional anisotropy (FA) in differentiating glioma recurrence from pseudoprogression.</p><p><strong>Methods: </strong>The Cochrane Library, Scopus, PubMed, and the Web of Science were systematically searched. Study selection and data extraction were done by two investigators independently. The quality assessment of diagnostic accuracy studies was applied to evaluate the quality of the included studies. Combined sensitivity (SEN) and specificity (SPE) and the area under the summary receiver operating characteristic curve (SROC) with the 95% confidence interval (CI) were calculated.</p><p><strong>Results: </strong>Seven high-quality studies involving 246 patients were included. Quantitative synthesis of studies showed that the pooled SEN and SPE for MD were 0.81 (95% CI 0.70-0.88) and 0.82 (95% CI 0.70-0.90), respectively, and the value of the area under the SROC curve was 0.88 (95% CI 0.85-0.91). The pooled SEN and SPE for FA were 0.74 (95% CI 0.65-0.82) and 0.79 (95% CI 0.66-0.88), respectively, and the value of the area under the SROC curve was 0.84 (95% CI 0.80-0.87).</p><p><strong>Conclusions: </strong>This meta-analysis showed that both MD and FA have a high diagnostic accuracy in differentiating glioma recurrence from pseudoprogression.</p><p><strong>Registration: </strong>PROSPERO protocol: CRD42024501146.</p>","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1177-1185"},"PeriodicalIF":2.9000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2024.2415404","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To evaluate the diagnostic accuracy of diffusion tensor imaging (DTI)-derived metrics mean diffusivity (MD) and fractional anisotropy (FA) in differentiating glioma recurrence from pseudoprogression.

Methods: The Cochrane Library, Scopus, PubMed, and the Web of Science were systematically searched. Study selection and data extraction were done by two investigators independently. The quality assessment of diagnostic accuracy studies was applied to evaluate the quality of the included studies. Combined sensitivity (SEN) and specificity (SPE) and the area under the summary receiver operating characteristic curve (SROC) with the 95% confidence interval (CI) were calculated.

Results: Seven high-quality studies involving 246 patients were included. Quantitative synthesis of studies showed that the pooled SEN and SPE for MD were 0.81 (95% CI 0.70-0.88) and 0.82 (95% CI 0.70-0.90), respectively, and the value of the area under the SROC curve was 0.88 (95% CI 0.85-0.91). The pooled SEN and SPE for FA were 0.74 (95% CI 0.65-0.82) and 0.79 (95% CI 0.66-0.88), respectively, and the value of the area under the SROC curve was 0.84 (95% CI 0.80-0.87).

Conclusions: This meta-analysis showed that both MD and FA have a high diagnostic accuracy in differentiating glioma recurrence from pseudoprogression.

Registration: PROSPERO protocol: CRD42024501146.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
磁共振弥散张量成像在区分假性进展和胶质瘤复发方面的诊断准确性:系统回顾和荟萃分析。
目的:评估弥散张量成像(DTI)得出的指标平均弥散度(MD)和分数各向异性(FA)在区分胶质瘤复发和假性进展方面的诊断准确性:方法:系统检索了 Cochrane Library、Scopus、PubMed 和 Web of Science。研究选择和数据提取由两名研究人员独立完成。采用诊断准确性研究质量评估方法来评价纳入研究的质量。计算了综合灵敏度(SEN)和特异度(SPE)以及接收者工作特征曲线下面积(SROC)和 95% 置信区间(CI):结果:共纳入了 7 项高质量的研究,涉及 246 名患者。研究的定量综合显示,MD的集合SEN和SPE分别为0.81(95% CI 0.70-0.88)和0.82(95% CI 0.70-0.90),SROC曲线下面积值为0.88(95% CI 0.85-0.91)。FA的汇总SEN和SPE分别为0.74(95% CI 0.65-0.82)和0.79(95% CI 0.66-0.88),SROC曲线下的面积值为0.84(95% CI 0.80-0.87):这项荟萃分析表明,MD和FA在区分胶质瘤复发和假性进展方面都具有很高的诊断准确性:注册:PROSPERO 协议:CRD42024501146。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.10
自引率
3.00%
发文量
100
审稿时长
4-8 weeks
期刊介绍: Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.
期刊最新文献
Unlocking survival benefits: primary tumor resection in de novo stage IV breast cancer patients. Statin use and ovarian cancer outcomes. Development of a nomogram for predicting postoperative recurrence of cervical intraepithelial neoplasia using immunohistochemical and clinical parameters. Impact of the 21-gene recurrence score testing on chemotherapy selection and clinical outcomes in T3N0 luminal breast cancer. The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1